Pirfenidone could decrease paraquat-induced pulmonary fibrosis in rats  by Seifirad, Soroush
at SciVerse ScienceDirect
Tzu Chi Medical Journal 25 (2013) 130Contents lists availableTzu Chi Medical Journal
journal homepage: www.tzuchimedjnl .comLetter to the Editor
Pirfenidone could decrease paraquat-induced pulmonary ﬁbrosis in ratsTo the Editor,
I read with interest the following recently published article in
your journal “Can pirfenidone prevent paraquat-induced pulmo-
nary ﬁbrosis? – A hypothesis” [1].
I am writing to present the results of our recently published
study which surprisingly tried to answer the same question [2].
In an experimental animal study, we compared the efﬁcacy of pir-
fenidone with that of conventional antioxidants in preventing pul-
monary ﬁbrosis and increasing the survival of rats with acute
paraquat poisoning. In our study (ﬁrst presented at the 10th Lung
Science Conference, April 2012, Estoril, Portugal) [3], pirfenidone
decreased paraquat-induced lung ﬁbrosis (p < 0.001) despite the
fact that antioxidants did not (p < 0.413). The increase in the sur-
vival of pirfenidone -treated rats was insigniﬁcant compared with
the antioxidant- treated group. This study showed that pirfenidone
is able to decrease pulmonary ﬁbrosis following paraquat poisoning
in a rat model.
With respect to our ﬁndings, it seems that treatment with
pirfenidone might decrease pulmonary ﬁbrosis due to paraquat
poisoning in rats. In addition, the anti-inﬂammatory properties of
pirfenidone [4–6] may also decrease the acute complications of
paraquat poisoning. Larger animal studies and clinical investiga-
tions are needed to investigate further the efﬁcacy of pirfenidone
in paraquat poisoning.
Future clinical trials are necessary to approve pirfenidone in
the treatment protocol of patients with paraquat poisoning.
Moreover, it would be interesting to know whether higher doses1016-3190/$ – see front matter Copyright  2013, Buddhist Compassion Relief Tzu Chi
http://dx.doi.org/10.1016/j.tcmj.2013.03.002or longer periods of treatment with pirfenidone increase its
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